Since the discovery of the human immunodeficiency virus (HIV) in 1983, dramatic progress
has been made in the development of novel antiviral drugs. The HIV epidemic fuelled the …

Recent advances in molecular biology have led to the development of novel small
molecules that target specific viral proteins of the hepatitis C virus (HCV) life cycle. These …

Nitazoxanide (NTZ), a thiazolide anti-infective, is active against anaerobic bacteria,
protozoa, and a range of viruses in cell culture models, and is currently in phase II clinical …

Hepatitis C virus (HCV) is a hepatotropic virus that affects millions of human lives worldwide.
Direct-acting antiviral (DAA) regimens are the most effective HCV treatment option …

The emergence of drug-resistance-inducing mutations in Hepatitis C virus (HCV) coupled
with genotypic heterogeneity has made targeting NS3/4A serine protease difficult. In this …

We characterized the selective advantage profiles of a panel of hepatitis C virus (HCV) NS3
protease mutants with three HCV protease inhibitors (PIs), BILN-2061, ITMN-191, and VX …

Hepatitis C virus (HCV) is a major cause of liver disease worldwide. HCV is able to evade
host defense mechanisms, including both innate and acquired immune responses, to …

Protease inhibitors (PIs) have proven to be effective adjuncts to interferon/ribavirin treatment
of hepatitis C virus (HCV) infections. Little clinical or in vitro data exists, however, on their …

Computational chemistry has always played a key role in anti-viral drug development. The
challenges and the quickly rising public interest when a virus is becoming a threat has …

Hepatitis C virus (HCV) is a human pathogen with high morbidity. The HCV NS3/4A
protease is essential for viral replication and is one of the top three drug targets. Several …